Allied Market Research
Loading...
0

Viral Vectors and Plasmid DNA Manufacturing Market Expected to Reach $4.97 Billion by 2027

 

Report Code : A02348

quote growth of the global viral vector and plasmid DNA manufacturing market is driven by rise in funding for R&D activities pertaining to gene therapy, rise in prevalence of cancer, viral infection, & genetic disorders, and increase in awareness regarding gene therapy. quote

Onkar Sumant
Manager, Healthcare at Allied Market Research

Get 20% Free Customization In This Report
Follow us on Social Media:       
 

According to a new report published by Allied Market Research, titled, “Viral Vectors and Plasmid DNA Manufacturing Market by Product, Application, And Region: Opportunity Analysis and Industry Forecast, 2019-2027,” 

The viral vectors and plasmid DNA manufacturing market size was valued at $918.37 million in 2019 and is projected to reach $4,978.54 million by 2027, registering a CAGR of 24.9% from 2020 to 2027. North America was the highest contributor to the viral vectors and plasmid DNA manufacturing market in 2019; however, Asia-Pacific is anticipated to witness the fastest growth rate throughout the forecast period.

Gene therapy has evolved as a favorable treatment option for various diseases (especially those with no cure at present) such as viral infections, cancers, and inherited disorders. Gene therapy and genetically modified therapy involve use of a therapeutic DNA (the gene of interest) in cells. The process of gene transfer into cells is achieved by application of vectors. Over the past few years, several viral and non-viral vectors (plasmid DNAs) have been standardized and optimized for this purpose. Viral vectors carry genetic material into cells by manipulating molecular mechanisms by which viruses transmit their genomes to other cells for infection. It can occur in vivo or in vitro. Plasmid carriers are artificially constructed on the basis of natural plasmids to adapt to laboratory operations.

This pandemic has disrupted growth in many economies across various domains. This pandemic is expected to present growth opportunities for viral vectors and plasmid DNA manufacturing market in near future. For this COVID-19, several viral vector, recombinant protein, live attenuated virus, and nucleic acid-based vaccines are in (pre)clinical development. Viral vector vaccines consist of a recombinant virus (which is the viral vector), frequently attenuated to reduce its pathogenicity, in which genes encoding viral antigen(s) have been cloned using recombinant DNA methods. Vector vaccines can either be replicating or non-replicating. The major advantage of these vector-based vaccines is that a single dose can be sufficient for protection. In addition, companies in the viral vector manufacturing market are increasing their production facilities.

Rise in funding for R&D activities pertaining to gene therapy; rise in prevalence of cancer, viral infection, & genetic disorders; and increase in awareness regarding gene therapy are the major factors that boost the viral vectors and plasmid DNA manufacturing market growth. However, high cost associated with gene therapies and risk of mutagenesis and other impediments in gene therapy restrain the market growth. 

The impact of driving factors is expected to surpass that of the restraints. Moreover, rise in demand for synthetic genes and untapped potential for emerging markets are expected to provide new opportunities for market players in the future. However, possible insertional mutagenesis and high cost of gene therapies impede the market growth. Moreover, technological advancements to alleviate challenges caused by traditional methods of vector production provide lucrative opportunities for the manufacturers in the industry.

The cancer segment generated the highest revenue of in 2019, and is anticipated to continue this trend in the future. Requirement for quality drugs and versatile therapies for treatment are expected to boost growth of this segment. In addition, the inherited disorders segment is anticipated to grow at the highest CAGR from 2020 to 2027. 

North America held the highest viral vectors and plasmid DNA manufacturing market share of million in 2019, owing to high prevalence rate of cancer and modern healthcare facilities. Adoption of experimental medicines and growth in awareness regarding gene therapy are expected to boost the North America market. Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to rapid industrialization in the area, increase in disposable income, and surge in government initiatives to modernize healthcare infrastructure.

The global viral vectors and plasmid DNA manufacturing market is segmented on the basis of product, application, and region. On the basis of product, it is divided into plasmid DNA, viral vectors, and non-viral vectors. By application, it is categorized into cancer, inherited disorders, viral infections, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings Of The Study

  • By product, the viral vector segment accounted for the largest market share in 2019.
  • By application, inherited disorder segment is expected to grow at the highest CAGR during the forecast period
  • North America held the major share of the viral vectors and plasmid DNA manufacturing market at CAGR of 23.4%.

The report provides some of the key players operating in the market include Cognate BioServices, Inc., Catalent Pharma Solutions, Fujifilm Holdings Corporation, Johnson & Johnson, Sanofi Corporation, F. Hoffmann-LA Roche Ltd, 4D Molecular Therapeutics, Sirion Biotech GmbH, Voyager therapeutics, and Thermo Fisher Scientific, Inc.

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com

 

For Media Inquiries, Please Contact

Tushar Nagose
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at
media@alliedmarketresearch.com

 
 

First time buyer?
Check offers and discount on this report
To get this report

 
Click Here
 
 

quote Viral Vectors and Plasmid DNA Manufacturing Market by Product (Plasmid DNA, Viral Vectors, and Non-Viral Vectors) and Application (Cancers, Inherited Disorders, Viral Infections and Others): Global Opportunity Analysis and Industry Forecast, 2019-2027 quote

View Report
 
 
Avenue Video Loading...

Avenue: Entire Library membership of Allied Market Research Reports at your disposal

  • Avenue is an innovative subscription-based online report database.
  • Avail an online access to the entire library of syndicated reports on more than 4,040 niche industries and company profiles on more than 12,953 firms across 11 domains.
  • A cost-effective model tailored for entrepreneurs, investors, and students & researchers at universities.
  • Request customizations, suggest new reports, and avail analyst support as per your requirements.
  • Get an access to the library of reports at any time from any device and anywhere.

 
 

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers

 

Featured Readings

 
rep-img

Published Date Jan 2021

Surgical Equipment Market

Download Sample
rep-img

Published Date Nov 2020

Medical Implant Market

Download Sample
 

Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

 
Get Industry Data Alerts
 

Buy Full Version
"Viral Vectors and Plasmid DNA Manufacturing Market"
Purchase Enquiry